MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Axsome Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

107.41 -2.09

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

107.33

Max

109.38

Galvenie mērījumi

By Trading Economics

Ienākumi

-10M

-75M

Pārdošana

14M

119M

EPS

-1.54

Peļņas marža

-63.075

Darbinieki

683

EBITDA

-10M

-71M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+58.81% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-458M

5.8B

Iepriekšējā atvēršanas cena

109.5

Iepriekšējā slēgšanas cena

107.41

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Axsome Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 3. apr. 23:04 UTC

Top Ziņas

JPMorgan Raises Risk of U.S., Global Recession to 60%

2025. g. 3. apr. 22:40 UTC

Galvenie tirgus virzītāji

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

2025. g. 3. apr. 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

2025. g. 3. apr. 18:51 UTC

Iegādes, apvienošanās, pārņemšana

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

2025. g. 3. apr. 23:43 UTC

Tirgus saruna

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

2025. g. 3. apr. 23:41 UTC

Tirgus saruna

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

2025. g. 3. apr. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

2025. g. 3. apr. 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

2025. g. 3. apr. 21:43 UTC

Top Ziņas
Peļņas

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 3. apr. 20:43 UTC

Tirgus saruna

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

2025. g. 3. apr. 20:34 UTC

Top Ziņas

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

2025. g. 3. apr. 20:23 UTC

Top Ziņas

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

2025. g. 3. apr. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

2025. g. 3. apr. 19:55 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 3. apr. 19:55 UTC

Tirgus saruna

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

2025. g. 3. apr. 19:21 UTC

Tirgus saruna

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

2025. g. 3. apr. 19:15 UTC

Tirgus saruna

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

2025. g. 3. apr. 18:45 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 3. apr. 18:45 UTC

Tirgus saruna

Gold Drops In Tariff Fallout -- Market Talk

2025. g. 3. apr. 18:39 UTC

Tirgus saruna

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

2025. g. 3. apr. 18:38 UTC

Top Ziņas

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

2025. g. 3. apr. 18:30 UTC

Top Ziņas

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

2025. g. 3. apr. 18:20 UTC

Tirgus saruna

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

2025. g. 3. apr. 18:18 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 3. apr. 18:17 UTC

Tirgus saruna

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

2025. g. 3. apr. 18:04 UTC

Tirgus saruna

US Sees More Job Openings in Construction, Transportation -- Market Talk

2025. g. 3. apr. 17:55 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Axsome Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

58.81% augšup

Prognoze 12 mēnešiem

Vidējais 174.29 USD  58.81%

Augstākais 216 USD

Zemākais 133 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Axsome Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

17 ratings

17

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

107 / 113.5Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Neutral Evidence

Ilgtermiņā

Strong Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.